Dr. Katherine J. Willingham, MD

Dr. Willingham practices at Stormont Vail Hospital in Topeka, Kansas, part of Stormont Vail Health.

Dr. Willingham's NPI, 1245262435, was assigned on July 7, 2006. Dr. Willingham graduated from University of Texas Southwestern Medical School at Dallas in 1997. Dr. Willingham holds Kansas license 04-29268.

Dr. Willingham's primary practice is Stormont Vail Hospital, at 1500 Sw 10th Avenue, Topeka, KS 66604 in Shawnee County. The practice phone is (785) 354-6121.

Dr. Willingham's primary practice is Stormont Vail Hospital in Topeka, Kansas, part of Stormont Vail Health. Dr. Willingham is also affiliated with The University of Kansas Health System St. Francis Campus. The medical group on file is Select Rehabilitation. Dmand AI also links Dr. Willingham to 1 more hospital, 5 home health agencies, 2 group practices and clinics, 1 skilled nursing facility and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Willingham practices, 11 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Willingham's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Willingham is licensed in Kansas.

CMS data shows 3,735 Medicare services from Dr. Willingham across 20 procedure codes in 2024, for 582 Medicare patients. Medicare paid $199,895 for them. Every service was in an office.

CMS counts 582 Medicare patients who saw Dr. Willingham in 2024. The largest group is 65 to 74, with 260 patients. 74% of them have high cholesterol, and 65% have high blood pressure. 4% are also on Medicaid. Their average risk score is 0.91, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Willingham's median patient age at 62, with 82% women.

In 2024, Dr. Willingham wrote 9,544 Medicare Part D claims for 622 patients. 88% of them were for generic drugs. CMS names the drug for 8,967 of them, across 142 drugs with 11 or more claims each, at $524,482 in total drug cost. In 2023, CMS named 8,662 claims across 138 drugs.

Dr. Willingham accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Willingham as offering telehealth.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Willingham to 9 clinical trials. 2 are still active or recruiting. Conditions studied include Cognitive Dysfunction, Diabetes Mellitus, Type 2 and Diabetes Mellitus. Eli Lilly and Company sponsors the most, 8. Open Payments lists research payments to Dr. Willingham that name 10 trials.

CMS Open Payments shows 234 general payments to Dr. Willingham from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 80% of the total. Eli Lilly and Company paid the most, $1,209. It also lists 21 research payments totaling $20,016 from 2016 to 2024, naming 10 clinical trials.

Dr. Willingham graduated from University of Texas Southwestern Medical School at Dallas in 1997.